Thoratec Takes Over Development Of Terumo’s DuraHeart II VAD
This article was originally published in The Gray Sheet
Executive Summary
Thoratec paid $13 million plus future milestone commitments worth up to $43.5 million for the next-generation ventricular assist technology, which it hopes will be ready for human implants by 2016.